<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/082E3C1A-59C5-4E8A-BBC9-AB9D3571AE75"><gtr:id>082E3C1A-59C5-4E8A-BBC9-AB9D3571AE75</gtr:id><gtr:name>Sanford Burnham Medical Research Inst</gtr:name><gtr:address><gtr:line1>10901 North Torrey Pines Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FE1EC3EB-3D38-4ABB-94B2-8429AC475C8F"><gtr:id>FE1EC3EB-3D38-4ABB-94B2-8429AC475C8F</gtr:id><gtr:name>Northwestern University</gtr:name><gtr:address><gtr:line1>633 Clark Street</gtr:line1><gtr:postCode>60208</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A3C8BDDA-C539-4B60-B80C-EFD9B1165849"><gtr:id>A3C8BDDA-C539-4B60-B80C-EFD9B1165849</gtr:id><gtr:name>Salk Institute for Biological Studies</gtr:name><gtr:address><gtr:line1>Salk Institute for Biological Studies</gtr:line1><gtr:line2>PO Box 85800</gtr:line2><gtr:postCode>CA 92186 5</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Immunology Infection and Inflam Diseases</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/082E3C1A-59C5-4E8A-BBC9-AB9D3571AE75"><gtr:id>082E3C1A-59C5-4E8A-BBC9-AB9D3571AE75</gtr:id><gtr:name>Sanford Burnham Medical Research Inst</gtr:name><gtr:address><gtr:line1>10901 North Torrey Pines Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FE1EC3EB-3D38-4ABB-94B2-8429AC475C8F"><gtr:id>FE1EC3EB-3D38-4ABB-94B2-8429AC475C8F</gtr:id><gtr:name>Northwestern University</gtr:name><gtr:address><gtr:line1>633 Clark Street</gtr:line1><gtr:postCode>60208</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A3C8BDDA-C539-4B60-B80C-EFD9B1165849"><gtr:id>A3C8BDDA-C539-4B60-B80C-EFD9B1165849</gtr:id><gtr:name>Salk Institute for Biological Studies</gtr:name><gtr:address><gtr:line1>Salk Institute for Biological Studies</gtr:line1><gtr:line2>PO Box 85800</gtr:line2><gtr:postCode>CA 92186 5</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FA473957-A6EE-4164-867C-CEF3FACBFF3C"><gtr:id>FA473957-A6EE-4164-867C-CEF3FACBFF3C</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Henry</gtr:otherNames><gtr:surname>Malim</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0401570"><gtr:id>9C4B8BBD-4E98-44B1-8835-C948A48E21A5</gtr:id><gtr:title>HIV-Host Interactions</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0401570</gtr:grantReference><gtr:abstractText>As adult, paediatric and adolescent HIV infections continue to spread worldwide, the need to augment anti-retroviral treatments remains of the utmost importance. This is illustrated by the lack of an effective HIV vaccine, and the economic, compliance, toxicity and viral resistance concerns that accompany current therapies targeted against the viral proteins reverse transcriptase (RT) and protease (PR). Accordingly, considering other HIV (or human) proteins as potential targets for new generations of anti-virals is a crucial goal of current AIDS research. Through laboratory-based studies, we discovered that an HIV protein, called Vif, is essential for virus growth because it blocks the activity of two human cell proteins, APOBEC3G and APOBEC3F, that otherwise prevent virus infection. Importantly, the APOBEC3G and APOBEC3F proteins work by inactivating the genome of HIV by a process termed hypermutation. Thus, a logical therapeutic strategy is to unlock the natural anti-HIV function of the APOBEC proteins by suppressing their negative regulation by Vif. For this approach to be pursued rationally, the biological principles that underpin all aspects of APOBEC protein function must be understood with greater precision. Specifically, we will investigate the details of how the APOBEC proteins mutate the HIV genome, how this process is regulated, and how HIV itself is selected as a target for hypermutation. We aim to define which elements of the APOBEC proteins are essential for anti-viral activity, and how they are recognised and suppressed by Vif. We will also undertake experiments to define the molecular structures of Vif and the APOBEC proteins in three-dimensions, since this will be essential for future efforts to design useful drugs. Finally, we will search for additional human cell proteins that influence Vif or APOBEC protein function, and whose manipulation may also be therapeutically exploitable. The Public Relations Dept of KCL is primarily responsible for communicating our work to the public; and a ?Directory of Experts? is maintained that enables members of the general public to identify academics willing to discuss their specialist area. For instance, Prof Malim has given numerous interviews to members of the press, has appeared on television and has been consulted by the BBC on the content of future AIDS-related programming. He will also be an Associate Editor of a planned public access journal, PLoS Pathogens, has given overview seminars on the value of basic science research at Community Liaison Meetings, and helps organise Conferences attended by members of the HIV/AIDS community.</gtr:abstractText><gtr:technicalSummary>Animal cells have developed many mechanisms to inhibit viral replication, and viruses have evolved diverse strategies to resist these effects. This balance is exemplified by HIV Vif, an essential virus-encoded protein that is required for replication in primary human CD4 T cells and, presumably, for viral growth during natural infection of humans. Vif acts by suppressing the innate anti-viral properties of the cellular cytidine deaminases APOBEC3G and APOBEC3F. In Vif?s absence, these enzymes are packaged into budding virions, and then transferred to newly infected cells where they efficiently inhibit infection by hypermutating nascent minus-strand reverse transcripts (cDNAs) through the deamination of cytidine (C) to uridine (U). The protective role of Vif is exerted through bridging an interaction between these APOBEC proteins and a cullin5-SCF-like E3 ubiquitin ligase; this results in APOBEC protein polyubiquitination, proteasomal degradation and exclusion from virions. Here, we propose to employ cell culture-based virological assays, biochemical approaches and structural biology methodologies to understand more completely the mechanisms that underpin Vif function and the anti-HIV properties of the APOBEC enzymes. We will investigate the relationship between APOBEC-mediated hypermutation and the degradation of edited HIV cDNAs; particularly, by interfering with cellular DNA repair enzymes thought to target U-containing DNA, defining the phenotypes of recently isolated non-editing APOBEC3G mutant proteins, and by drawing comparisons with MLV infection. We will use molecular biological approaches to define which elements and motifs of the APOBEC proteins underlie these effects; how precisely they each contribute to function; how specificity for different virus substrates is determined; and how recognition and inhibition by Vif is dictated. Importantly, these structure-function analyses will be complemented by our continuing endeavours to determine the three-dimensional structures of Vif, APOBEC proteins and complexes thereof using X-ray crystallography and/or NMR. Finally, we will undertake experiments to identify additional cellular proteins that interact with APOBEC proteins and/or the cullin5-ubiquitin ligase and may contribute to the regulation of activity. Our focus will be on utilising affinity-tagged proteins or co-purification, but we will also perform an siRNA screen for E2 enzymes important for Vif function. Notably, these initiatives also have the potential to help define natural cell functions of the APOBEC proteins. In sum, this research will contribute to the broader understanding of HIV pathogenesis and innate mechanisms of viral resistance (and virus-mediated evasion), and should provide information important for anticipated future initiatives to exploit Vif/APOBEC as a therapeutic target for treating HIV/AIDS.</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1400000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northwestern University Chicago</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Northwestern University, Chicago</gtr:description><gtr:id>8155A7AA-B45A-4712-B2C0-85CB740068CE</gtr:id><gtr:impact>PMID: 19057663, 19587057, 20660203, 21697957, 22727223, 22915799, 23152537</gtr:impact><gtr:outcomeId>CFmcrce8yQS-1</gtr:outcomeId><gtr:partnerContribution>We collaborate on a number of projects addressing the contributions of APOBEC3 proteins to HIV transmission, pathogenesis following transmission, and viral sequence evolution.</gtr:partnerContribution><gtr:piContribution>I was a co-investigator on an NIH grant (AI070072), &amp;quot;The APOBEC/Vif Conflict and HIV Pathogenesis&amp;quot;. The lead PI is Dr Steve Wolinsky. The project addressed the contributions of APOBEC3 proteins to HIV transmission, pathogenesis following transmission, and viral sequence evolution. Our groups work together on various projects in this area, and members of my lab have undertaken short sabbaticals at Northwestern to learn new techniques.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biomedical Sciences KCL</gtr:department><gtr:description>King's College London, Randall Division</gtr:description><gtr:id>24B2A12A-E6EA-4485-97E1-1F3705B3939C</gtr:id><gtr:impact>PMID: 20532212, 24225024</gtr:impact><gtr:outcomeId>PYF1pR8mN7S-1</gtr:outcomeId><gtr:partnerContribution>We collaborated on structural biology projects concerning APOBEC3G, HIV-1 Vif and the cullin5/elonginBC E3 ubiquitin ligase complex</gtr:partnerContribution><gtr:piContribution>I was a co-investigator on a Wellcome Trust grant, &amp;quot;Structural and biochemical studies on the interaction of HIV-1 Vif with its partner ubiquitin ligase complex&amp;quot;. The other investigator was Dr Mark Sanderson. We provided DNA constructs, as well as biochemical and virological expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Tibotec</gtr:department><gtr:description>Tibotec</gtr:description><gtr:id>B3847604-9B4F-4658-A1D8-566A4BAC9516</gtr:id><gtr:impact>PMID: 19266078</gtr:impact><gtr:outcomeId>D43928E642D-1</gtr:outcomeId><gtr:partnerContribution>Tibotec supported one post in the lab to investigate structure-function and computer-assisted modelling questions relating to the human anti-viral protein APOBEC3G.</gtr:partnerContribution><gtr:piContribution>We provided reagents and expert opinion in this area. This funding ceased at the end of 2008.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northwestern University Chicago</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>HIV Immune Networks Team (HINT)</gtr:description><gtr:id>8F0B36FF-126F-4132-A94A-5CFD5F5D9E12</gtr:id><gtr:impact>A grant application entitled &amp;quot;A systems-level approach to studying HIV/AIDS susceptibility and substance abuse&amp;quot; has been submitted to the National Institute on Drug Abuse (NIDA)</gtr:impact><gtr:outcomeId>WVdfKooWk2s-1</gtr:outcomeId><gtr:partnerContribution>The Network contributes data, ideas and collaborative experiments regarding HIV-1 infection, and its control</gtr:partnerContribution><gtr:piContribution>We contribute data and ideas concerning the interactions between HIV-1 infection and innate immunity, focusing particularly on type 1 interferon.
I am a co-investigator on an NIH grant (DA033773) together with Steven M. Wolinsky (lead PI), Sumit K. Chandra, Adolfo Garc&amp;iacute;a-Sastra, Nevan J. Krogan &amp;amp; John A.T. Young, &amp;quot;A systems-level approach to studying HIV/AIDS susceptibility and substance abuse&amp;quot;. This supports aspects of HINT's research agenda</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanford-Burnham Medical Research Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>HIV Immune Networks Team (HINT)</gtr:description><gtr:id>430B666F-F6D9-4666-A25C-5D7A9B970454</gtr:id><gtr:impact>A grant application entitled &amp;quot;A systems-level approach to studying HIV/AIDS susceptibility and substance abuse&amp;quot; has been submitted to the National Institute on Drug Abuse (NIDA)</gtr:impact><gtr:outcomeId>WVdfKooWk2s-3</gtr:outcomeId><gtr:partnerContribution>The Network contributes data, ideas and collaborative experiments regarding HIV-1 infection, and its control</gtr:partnerContribution><gtr:piContribution>We contribute data and ideas concerning the interactions between HIV-1 infection and innate immunity, focusing particularly on type 1 interferon.
I am a co-investigator on an NIH grant (DA033773) together with Steven M. Wolinsky (lead PI), Sumit K. Chandra, Adolfo Garc&amp;iacute;a-Sastra, Nevan J. Krogan &amp;amp; John A.T. Young, &amp;quot;A systems-level approach to studying HIV/AIDS susceptibility and substance abuse&amp;quot;. This supports aspects of HINT's research agenda</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Salk Institute for Biological Studies</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>HIV Immune Networks Team (HINT)</gtr:description><gtr:id>2D99BBD0-FBB3-4EF7-8E06-A3239E812CB3</gtr:id><gtr:impact>A grant application entitled &amp;quot;A systems-level approach to studying HIV/AIDS susceptibility and substance abuse&amp;quot; has been submitted to the National Institute on Drug Abuse (NIDA)</gtr:impact><gtr:outcomeId>WVdfKooWk2s-2</gtr:outcomeId><gtr:partnerContribution>The Network contributes data, ideas and collaborative experiments regarding HIV-1 infection, and its control</gtr:partnerContribution><gtr:piContribution>We contribute data and ideas concerning the interactions between HIV-1 infection and innate immunity, focusing particularly on type 1 interferon.
I am a co-investigator on an NIH grant (DA033773) together with Steven M. Wolinsky (lead PI), Sumit K. Chandra, Adolfo Garc&amp;iacute;a-Sastra, Nevan J. Krogan &amp;amp; John A.T. Young, &amp;quot;A systems-level approach to studying HIV/AIDS susceptibility and substance abuse&amp;quot;. This supports aspects of HINT's research agenda</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Caf? Scientifique</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>555359B3-EB51-4B55-9843-9D5AAF8E6368</gtr:id><gtr:impact>Public Seminar, Caf&amp;eacute; Scientifique, Frisco, Colorado

no notable impact, beyond public dissemination</gtr:impact><gtr:outcomeId>F8E7F4D3A40</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>574045</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>R01 (USA)</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>AI070072</gtr:fundingRef><gtr:id>9D4D54B0-8845-4289-884C-1749AEBEE85B</gtr:id><gtr:outcomeId>73780DD03960</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>143720</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marie Curie Intra-European Fellowship for Dr Caroline Goujon</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:id>6ADE5D4E-4234-415B-BAE1-39FA4C5B883F</gtr:id><gtr:outcomeId>oeKbXhb5oQu0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240380</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>research grant</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>084280/Z/07/Z</gtr:fundingRef><gtr:id>443398A7-EEF5-4816-81D3-D4CC78B368D7</gtr:id><gtr:outcomeId>901F49D0E8E0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>229617</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Training Fellowship (for Medical Graduates)</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>098850/Z/12/Z</gtr:fundingRef><gtr:id>A3A7006D-966C-475D-A961-DDB4D6149340</gtr:id><gtr:outcomeId>JvFX9S38UWN</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>research grant</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>7FD4BDC9-018F-4056-AE35-FD1307D1620B</gtr:id><gtr:outcomeId>T86WXj3HzkP0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>365006</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>R01 (USA)</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>DA033773</gtr:fundingRef><gtr:id>DA77B717-CF77-42F0-AF0B-53FA9DB37525</gtr:id><gtr:outcomeId>bVPBiW4Rkwb</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A variety of human and primate cell lines expressing wild type or mutated human APOBEC3 proteins have been constructed</gtr:description><gtr:id>A26C265B-061D-4CC6-AFC0-06686E7FBF9E</gtr:id><gtr:impact>basic research findings</gtr:impact><gtr:outcomeId>4C9668CB6BB</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>APOBEC3 protein expressing cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Rabbit sera were raised following immunisation with synthetic peptides comprising the C-terminal sequences of the proteins</gtr:description><gtr:id>6F3E10DE-6B74-4FC3-9AAD-C7F906D67398</gtr:id><gtr:impact>These reagents are distributed through reagent programmes, commercially and collaboratively, and have been used extensively in laboratory research</gtr:impact><gtr:outcomeId>CC008821C2A</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Antibodies specific for human APOBEC3G and APOBEC3F proteins</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Expression vectors for HIV proteins, cellular proteins, as well as tagged and mutated derivatives thereof have been constructed in a variety of plasmid- and retrovirus-based vectors</gtr:description><gtr:id>E741EAD9-BDD7-49FA-AF8F-169B8970B291</gtr:id><gtr:impact>The work on APOBEC proteins as natural inhibitors of HIV/SIV infection has founded new fields of research, not only on these proteins but, more broadly, on cell-based mechanisms of virus resistance (TRIM, tetherin, etc). Much of this work relies on reagents such as those developed in this lab.</gtr:impact><gtr:outcomeId>859E5BC90B7</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Expression vectors for HIV- or cell-encoded proteins</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E7EA22E5-C87D-4FCF-82C8-3B75EBAAF155</gtr:id><gtr:title>Guidelines for naming nonprimate APOBEC3 genes and proteins.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e87cacb3c20fe51111fc5b69b864cf04"><gtr:id>e87cacb3c20fe51111fc5b69b864cf04</gtr:id><gtr:otherNames>LaRue RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>AC81273CF1D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08E98D0F-B234-4EA7-98DC-860BB4A9DF50</gtr:id><gtr:title>Hypermutation of an ancient human retrovirus by APOBEC3G.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a81a632ccb81418d28e440675a2d401b"><gtr:id>a81a632ccb81418d28e440675a2d401b</gtr:id><gtr:otherNames>Lee YN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>AFB7C04D484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D444E21C-1DDD-4E4C-9280-54D14079C4BA</gtr:id><gtr:title>Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42186008fbbe7ca8e97d030b07c1ae3d"><gtr:id>42186008fbbe7ca8e97d030b07c1ae3d</gtr:id><gtr:otherNames>Gallois-Montbrun S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>4A9FD98D903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EE08CEC-AC19-4A93-AFAF-6F241FADB4EC</gtr:id><gtr:title>HIV-1 accessory proteins--ensuring viral survival in a hostile environment.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08cdaef89f33d6b94fb92520b444ffcf"><gtr:id>08cdaef89f33d6b94fb92520b444ffcf</gtr:id><gtr:otherNames>Malim MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>B5D38EC9714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36D4BB95-DC9C-4B26-8E27-276647A4F98B</gtr:id><gtr:title>SRp40 and SRp55 promote the translation of unspliced human immunodeficiency virus type 1 RNA.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd04a534d326f56a32bfaa6203b6d739"><gtr:id>dd04a534d326f56a32bfaa6203b6d739</gtr:id><gtr:otherNames>Swanson CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>qC3tUQswGx4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FB632BE-3B30-4943-A654-4E5EDA4B52F0</gtr:id><gtr:title>Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/363ad5d61c060939ed60a0c5465c493f"><gtr:id>363ad5d61c060939ed60a0c5465c493f</gtr:id><gtr:otherNames>Baumert TF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>97BED558642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27512C24-2CEA-4C2D-96E4-22296BE2BA6D</gtr:id><gtr:title>Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acad78882d25f801f5874af5ec73f5a4"><gtr:id>acad78882d25f801f5874af5ec73f5a4</gtr:id><gtr:otherNames>Kim EY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5448f3d5d1b452.75582824</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71704432-6C02-4D0A-B477-0ACC1FA3840F</gtr:id><gtr:title>The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6129759e49f00144c4b8d4ff35f27a1a"><gtr:id>6129759e49f00144c4b8d4ff35f27a1a</gtr:id><gtr:otherNames>Fehrholz M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_14565_25_22170635</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22E7CE2C-0ABC-45D2-A356-C3CAF78F0287</gtr:id><gtr:title>Rationalisation of the differences between APOBEC3G structures from crystallography and NMR studies by molecular dynamics simulations.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d69104c0b0ec4d119bba9dd531cd524"><gtr:id>2d69104c0b0ec4d119bba9dd531cd524</gtr:id><gtr:otherNames>Autore F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>1EEE9F47A30</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FEB28F8-F7DD-42C5-99DA-A328890707CD</gtr:id><gtr:title>Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acad78882d25f801f5874af5ec73f5a4"><gtr:id>acad78882d25f801f5874af5ec73f5a4</gtr:id><gtr:otherNames>Kim EY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>Yz4RpFTnZKG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AA8C9FD-CD22-4A23-906B-B61585372E70</gtr:id><gtr:title>Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0081983a84256e14922a086b8b9919"><gtr:id>2d0081983a84256e14922a086b8b9919</gtr:id><gtr:otherNames>Gillick K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_14565_25_23152537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8934C396-8134-4596-838F-222733E89B5A</gtr:id><gtr:title>HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c289ea9f855e7d4ef862dedff62b35b1"><gtr:id>c289ea9f855e7d4ef862dedff62b35b1</gtr:id><gtr:otherNames>Phalora PK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_14565_25_22915799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB97C2E8-690E-4395-83C2-4A35C50711E5</gtr:id><gtr:title>Retrovirus RNA trafficking: from chromatin to invasive genomes.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd04a534d326f56a32bfaa6203b6d739"><gtr:id>dd04a534d326f56a32bfaa6203b6d739</gtr:id><gtr:otherNames>Swanson CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn><gtr:outcomeId>DF4B649D94F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8259B4F-32F1-457C-B6FA-0F9E06B773CF</gtr:id><gtr:title>The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c502649a70ad29daf9e80276dcc5f29"><gtr:id>0c502649a70ad29daf9e80276dcc5f29</gtr:id><gtr:otherNames>Bergeron JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>3C8C707D9CF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47139CCE-0606-4B68-9924-C78B2A0953F0</gtr:id><gtr:title>APOBEC-mediated viral restriction: not simply editing?</gtr:title><gtr:parentPublicationTitle>Trends in biochemical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb5b7bf1defdbf5ea07c22c565ae56d7"><gtr:id>fb5b7bf1defdbf5ea07c22c565ae56d7</gtr:id><gtr:otherNames>Holmes RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0968-0004</gtr:issn><gtr:outcomeId>42EBD45A621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2739F012-7D33-454A-9031-F4C79CB1FF9E</gtr:id><gtr:title>APOBEC3G inhibits elongation of HIV-1 reverse transcripts.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f34fd810c25c8c8a184709b013beb0e"><gtr:id>0f34fd810c25c8c8a184709b013beb0e</gtr:id><gtr:otherNames>Bishop KN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>1007473B79C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE25E092-6D77-4E3E-B0E0-13F3D4D9819E</gtr:id><gtr:title>Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42186008fbbe7ca8e97d030b07c1ae3d"><gtr:id>42186008fbbe7ca8e97d030b07c1ae3d</gtr:id><gtr:otherNames>Gallois-Montbrun S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>7DB453969C6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F6CE8FC-9A13-4CCD-A43F-BD5E1EDEABEF</gtr:id><gtr:title>Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a22858f758e08c8666a044713dd48bb7"><gtr:id>a22858f758e08c8666a044713dd48bb7</gtr:id><gtr:otherNames>Huthoff H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>38A5502D693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AE3BE59-BA60-4CB0-AF96-4DDCB7C9D59B</gtr:id><gtr:title>Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e7ffd30d3d558be5c0122ed5a8f57f0"><gtr:id>8e7ffd30d3d558be5c0122ed5a8f57f0</gtr:id><gtr:otherNames>Koning FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>cJB7RK6bzJ1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15A4AE60-521C-40B1-8077-97DBF1594374</gtr:id><gtr:title>APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb5b7bf1defdbf5ea07c22c565ae56d7"><gtr:id>fb5b7bf1defdbf5ea07c22c565ae56d7</gtr:id><gtr:otherNames>Holmes RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>26AC37ECCDD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>685E2259-3D42-4151-A331-1BCE1B326C7F</gtr:id><gtr:title>RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a22858f758e08c8666a044713dd48bb7"><gtr:id>a22858f758e08c8666a044713dd48bb7</gtr:id><gtr:otherNames>Huthoff H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>8A9A447914C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDA25122-C665-4550-8C01-B24BA2408472</gtr:id><gtr:title>Matrix mediates the functional link between human immunodeficiency virus type 1 RNA nuclear export elements and the assembly competency of Gag in murine cells.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a84d7fc0c78b0b04b5b583554dc7ff07"><gtr:id>a84d7fc0c78b0b04b5b583554dc7ff07</gtr:id><gtr:otherNames>Sherer NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>1D71ADB8C14</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F2FA099-0962-4F00-A588-1C16FE1F3019</gtr:id><gtr:title>AIDS/HIV. HIV interplay with SAMHD1.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b80e4206e65c27027c5eb4c5816ed08"><gtr:id>2b80e4206e65c27027c5eb4c5816ed08</gtr:id><gtr:otherNames>Schaller T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>pm_14565_25_22422971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>560E29C3-EC92-42E6-B05F-1BB3FA296D90</gtr:id><gtr:title>Gold nanoparticle-mediated gene delivery induces widespread changes in the expression of innate immunity genes.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acad78882d25f801f5874af5ec73f5a4"><gtr:id>acad78882d25f801f5874af5ec73f5a4</gtr:id><gtr:otherNames>Kim EY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>F59vZxLuu2P</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F1AE9F6-4532-4A33-AAF3-53B71346E31C</gtr:id><gtr:title>APOBEC proteins and intrinsic resistance to HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08cdaef89f33d6b94fb92520b444ffcf"><gtr:id>08cdaef89f33d6b94fb92520b444ffcf</gtr:id><gtr:otherNames>Malim MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>9F1C3AEFBD3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27FCA008-ADC6-436F-B78E-F0CB8AD4D352</gtr:id><gtr:title>HIV-1 and interferons: who's interfering with whom?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ef4bc924b19c7e189b6f654810964e"><gtr:id>68ef4bc924b19c7e189b6f654810964e</gtr:id><gtr:otherNames>Doyle T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1740-1526</gtr:issn><gtr:outcomeId>56b88a0ca42b54.41736026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DBDCC12-B5C4-4426-B9F6-BB40859F673D</gtr:id><gtr:title>Endogenous MOV10 inhibits the retrotransposition of endogenous retroelements but not the replication of exogenous retroviruses.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01aac83b8549060d77dffdc6ae1fd282"><gtr:id>01aac83b8549060d77dffdc6ae1fd282</gtr:id><gtr:otherNames>Arjan-Odedra S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>pm_14565_25_22727223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06CCEF7B-F693-4CBF-8464-DAC8BD6EF398</gtr:id><gtr:title>Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e7ffd30d3d558be5c0122ed5a8f57f0"><gtr:id>8e7ffd30d3d558be5c0122ed5a8f57f0</gtr:id><gtr:otherNames>Koning FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>3B18359BCC8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0327C068-30BB-4207-BACC-8BEF7D0AA620</gtr:id><gtr:title>Evolution of a species-specific determinant within human CRM1 that regulates the post-transcriptional phases of HIV-1 replication.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a84d7fc0c78b0b04b5b583554dc7ff07"><gtr:id>a84d7fc0c78b0b04b5b583554dc7ff07</gtr:id><gtr:otherNames>Sherer NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>EQvYXK9uqVQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>287CC266-2EBB-4FB3-9253-6A11768DC655</gtr:id><gtr:title>SnapShot: HIV-1 proteins.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd04a534d326f56a32bfaa6203b6d739"><gtr:id>dd04a534d326f56a32bfaa6203b6d739</gtr:id><gtr:otherNames>Swanson CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>B9B6705AEEE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E52647BA-F9AD-4CBE-80F8-391B2627CEC0</gtr:id><gtr:title>HIV Restriction Factors and Mechanisms of Evasion.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor perspectives in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08cdaef89f33d6b94fb92520b444ffcf"><gtr:id>08cdaef89f33d6b94fb92520b444ffcf</gtr:id><gtr:otherNames>Malim MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2157-1422</gtr:issn><gtr:outcomeId>pm_14565_25_22553496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF80658A-41D0-4855-B05C-F52A7DA50748</gtr:id><gtr:title>Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74a0ff0ef24bc64a468e4f87b0b43c0b"><gtr:id>74a0ff0ef24bc64a468e4f87b0b43c0b</gtr:id><gtr:otherNames>Goujon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>iLxRe4shftf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE28A1EC-F627-46C1-9EFB-22AFD737D687</gtr:id><gtr:title>Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f34fd810c25c8c8a184709b013beb0e"><gtr:id>0f34fd810c25c8c8a184709b013beb0e</gtr:id><gtr:otherNames>Bishop KN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>FAED9F536CC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D85DA92-B0E4-4A8F-A66C-AF91AF993E10</gtr:id><gtr:title>TRIM5 alpha cytoplasmic bodies are highly dynamic structures.</gtr:title><gtr:parentPublicationTitle>Molecular biology of the cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fea1d443be28d2ed4910ca829c5e48af"><gtr:id>fea1d443be28d2ed4910ca829c5e48af</gtr:id><gtr:otherNames>Campbell EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1059-1524</gtr:issn><gtr:outcomeId>C98556375B4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6FA82E4-8E8D-43A5-8016-455A65314725</gtr:id><gtr:title>How Representative Are Research Tissue Biobanks of the Local Populations? Experience of the Infectious Diseases Biobank at King's College, London, UK.</gtr:title><gtr:parentPublicationTitle>Biopreservation and biobanking</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25ebe5f248f4ee7e04bf269bf8085d97"><gtr:id>25ebe5f248f4ee7e04bf269bf8085d97</gtr:id><gtr:otherNames>Kozlakidis Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1947-5543</gtr:issn><gtr:outcomeId>NW9WNkjZ6rM</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0401570</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>